ArticleNature immunology2025
Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer.
Abstract read
In one paragraph
Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Integrated single-cell multiomics reveals neutrophil-driven immune-metabolic reprogramming of Kupffer cells via thrombospondin-1/CD36 after surgical stress.JCI insight · 2026Article
- Senescent Cell Heterogeneity: Tissue-Dependent Signatures and Age Dynamics Revealed by Human scRNA-Seq Data.International journal of molecular sciences · 2026Article
- Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation.Molecular medicine (Cambridge, Mass.) · 2026Review
- CD47 and FOXP3Cancers · 2026Review
- Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression.International journal of molecular sciences · 2026Review
- Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.Smart molecules : open access · 2026Review
- A Biomimetic Nanoparticle System Intercepts and Degrades Thrombospondin-1 to Restore Vascular Homeostasis After Ischemic Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Analysis of Prognostic Significance of CD47 Expression in Newly Diagnosed Large B Cell Lymphoma.Life (Basel, Switzerland) · 2026Article
- Development and validation of an interpretable prognostic model for bladder cancer based on lactylation associated genes using SHAP analysis.Discover oncology · 2026Article
- The tumor microenvironment in leukemia: molecular pathways of immune evasion.Frontiers in immunology · 2026Review
- Targeting CD47-mediated cancer senescence, a novel strategy for cancer immunotherapy.Frontiers in immunology · 2026Review
- Myeloid Cell-Derived Thrombospondin-1 Mediates Anti-Metastatic Effects of Histamine Dihydrochloride in B16 Melanoma.ImmunoTargets and therapy · 2026Article
- β-Glucan in antiviral defense: mechanisms, immune modulation, and therapeutic prospects.Folia microbiologica · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Chien-Huan WengSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-5478-9188
Anais AssouvieSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Lauren DongSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0009-0005-8485-0380
Jean-Christophe BeltraParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Sadna BudhuSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Levi MangarinSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1219-6998
Yacine MaroufSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-4621-1407
Lucia Morgado-PalacinSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Cailian LiuSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Sébastien MonetteLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY, USA.
Jonathan F KhanSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-3444-8108
Isabell SchulzeSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9672-7655
Dmitriy ZamarinMemorial Sloan-Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0094-0161
Linda HamadeneSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Fadi SamaanMemorial Sloan-Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9124-5414
Daniel HirschhornSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Stephane PourpeMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
David SchröderMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Roberta ZappasodiSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-7031-6671
Pamela M HollandSurface Oncology Inc., Cambridge, MA, USA.
Niroshana AnandasabapathySandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
E John WherryParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0477-1956
Jedd D WolchokSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. jwolchok@med.cornell.edu.ORCID http://orcid.org/0000-0001-6718-2222
Taha MerghoubSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. tmerghoub@med.cornell.edu.ORCID http://orcid.org/0000-0002-1518-5111
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MInterrogating unique DC adaptations to tissue to promote barrier immunity and toleranceR01AR080436 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Niroshana Anandasabapathy · 2022 to 2026
$3.5MImage-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapyR01CA249294 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KESHARI, KAYVAN R, MERGHOUB, TAHA · 2021 to 2025
$2.6MNew mechanisms governing skin tissue residency memory T cellsR01AR083208 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Niroshana Anandasabapathy · 2024 to 2026
$2.1MBreast Cancer Research Foundation (BCRF) BCRF-22-176; BCRF-23-176Ludwig Institute for Cancer Research (Ludwig Cancer Research) N/ANCI NIH HHS P30 CA008748NCI NIH HHS R01 CA249294NIAMS NIH HHS R01 AR080436NIAMS NIH HHS R01 AR083208U.S. Department of Defense (United States Department of Defense) W81XWH-20-1-0723U.S. Department of Defense (United States Department of Defense) W81XWH-21-1-0101U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA008748
Abstract
T cell exhaustion is a major barrier to effective cancer immunotherapy. Although immune checkpoint blockade can reinvigorate exhausted T cells, not all patients achieve long-term responses, partly due to the refractory nature of terminally exhausted T cells. Beyond persistent antigen stimulation, the environmental drivers of exhaustion remain to be thoroughly characterized. Here we identify CD47 upregulation in tumor-infiltrating exhausted CD8
Indexed as
CD47 AntigenCD8-Positive T-LymphocytesNeoplasmsThrombospondin 1AnimalsCell Line, TumorHumansImmunotherapyLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLNFATC Transcription FactorsSignal TransductionT-Cell ExhaustionCD47 AntigenCD47 protein, humanCd47 protein, mouseNFATC Transcription FactorsThrombospondin 1thrombospondin-1, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.